DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics segments. Founded in 2000 and headquartered in Saluggia, Italy, the... DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics segments. Founded in 2000 and headquartered in Saluggia, Italy, the company develops and markets in vitro diagnostics reagent kits for detecting antibodies and antigens, serving healthcare, life sciences, and academic research sectors. With approximately 3,271 employees and 2024 revenue of $1,282.9 million, DiaSorin operates across North America, Europe, and key geographies like Italy. A pivotal milestone was the 2021 acquisition of Luminex Corp., enhancing its portfolio with advanced molecular diagnostic technologies such as the ARIES and VERIGENE Systems, xMAP Technology, and companion diagnostics kits for cystic fibrosis and infectious diseases detection. DiaSorin also engages in the Licensed Technology sector, providing instruments like LIAISON systems for hepatitis delta testing and bloodstream infection diagnostics, empowering precise clinical responses worldwide. Over 50 years of expertise underpin its role in advancing diagnostic solutions for doctors, patients, and research institutions.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by DiaSorin

We reviewed DiaSorin's website and available disclosure materials for the 2024 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review DiaSorin's data?

Start your 30-day free trial to request a data review for DiaSorin.

Start Free Trial

Legal Center Contact Us